Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Studies included
| Study | Level of evidence | Jadad | No. of hips | Male / Female | Mean age | Duration of symptoms |
|---|---|---|---|---|---|---|
| Di Sante et al. 2016(17) | Level I | 3 | 43 (22 HA + 21 PRP) | Ia 11/10 | 71 | not reported |
| Dallari et al. 2016(18) | Level I | 5 | 111 (44 PRP + 36 HA + 31 Both) | 20/24 | 50–59 | >4 months |
| Battaglia et al. 2013(19) | Level I | 4 | 100 (50 HA + 50 PRP) | 30/20 | 53 | 6–24 months |
Description of studies
| Study | OA grade | Mean FUP | Control | Outcome measures | Preparation | Complications |
|---|---|---|---|---|---|---|
| Di Sante et al. 2016(17) | KL: II i III | 16 weeks | HA | VAS, WOMAC | 8 mls blood, 4 mls PRP 3 weekly injections | None |
| Dallari et al. 2016(18) | KL: I–IV | 12 months | HA | VAS, WOMAC, HHS | 150 mls blood, 4 × 5 mls PRP 3 weekly injections | None |
| Battaglia et al. 2013(19) | KL: II, III i IV | 12 months | HA | VAS, HHS | 150 mls blood, 4 × 5 mls PRP 3 weekly injections | 1 superficial haematoma |